Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Standardization of acquisition protocols using PET/CT with 18F-Choline in prosta...
Journal Information
Vol. 39. Issue 4.
Pages 204-211 (July - August 2020)
Download PDF
More article options
Vol. 39. Issue 4.
Pages 204-211 (July - August 2020)
Original Article
Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer
Estandarización de los protocolos de adquisición mediante PET/TC con 18F-Colina en el cáncer de próstata
J.R. Garcia
Corresponding author

Corresponding author.
, M. Cozar, M. Soler, P. Bassa, E. Riera, M. Buxeda, E. Valls, J. Ferrer
Unidad PET CETIR ASCIRES Grupo biomédico, Esplugues de Llobregat, Barcelona, Spain
This item has received
Article information
Full Text
Download PDF
Figures (5)
Show moreShow less
Tables (3)
Table 1. Analysis by patients.
Table 2. Analysis by lesions.
Table 3. Metabolic pattern of the 18F-Choline deposits.
Show moreShow less

To standardize acquisition protocols for 18F-Choline PET/CT to prevent from urine interference, to determine the best time point for the whole-body study, and to assess whether “dual point” acquisition allows for differentiating malignant vs. benign lesions.


One hundred consecutive patients with prostate cancer were prospectively studied. Immediately after 18F-Choline injection, a pelvis study was acquired, and a whole-body was subsequently obtained 1 and 2h p.i. Mean SUVmax was obtained in regions and for every sequential imaging. Mean analysis (χ2) and SUV percentage change (2/1h; 1h/0min) were obtained. Metabolic pattern dynamics were assessed: accumulative vs. clearance. Patient follow-up after therapy and directed classification whenever ethically possible were performed.


Fifty-three prostate foci, without disturbing urinary activity was ever found on early images. Accumulative pattern in 42, with percentage increase was: 0min/1h: +16.7% (χ2 0.94); 1/2h: +10.0% (χ2 0.83). Clearance pattern in 11, with percentage decrease: 0min/1h: −21.4% (χ2 0.91): −7.7% (χ2 0.85), corresponding in 7 to initial staging and in 4 post-radiotherapy biochemical recurrence.

Every infradiaphragmatic uptake (n: 24) showed accumulative pattern, with percentage increase of +9.1% (χ2 0.97), all of them depicted on early imaging.

As for 12 supradiaphragmatic uptake, 8 of them showed clearance pattern with percentage decrease: −13.0% (χ2 0.95). Accumulative pattern showed in 4 of them with percentage increase +13.0% (χ2 0.96), thus being assessed as invasive/malignant.

Every bone uptake (n: 18) showed accumulative pattern, with percentage increase: +17.1% (χ2 0.95), all of them depicted on 1h imaging.


As for prostate assessment is concerned, dual point at 0min/1h proved to be the best procedure. As for supradiaphragmatic lymph-nodes detection, dual point with 1/2h performed best. As for infradiaphragmatic and bone involvement, as well as for inconclusive findings, the 2h imaging increased our diagnostic confidence.

18F-Choline PET/TC
Prostate cancer: Acquisition protocols

Estandarizar los protocolos de adquisición de 18F-Colina PET/TC, que permitan evitar la interferencia urinaria, evaluar el mejor tiempo del estudio de cuerpo completo y valorar si la «doble fase» permite la diferenciación entre lesiones benignas frente a malignas.


Estudio prospectivo que incluye 100 pacientes con cáncer de próstata: 31 estadificación y 69 recidiva bioquímica (32 posprostatectomía y 37 posradioterapia). Adquisición pélvica inmediatamente tras inyección de 18F-Colina y estudio de cuerpo completo, 1 y 2h p.i. Cálculo de media SUVmáx por territorios en todos los estudios secuenciales. Análisis de medias (χ2) y porcentaje de cambio del SUV (2/1h; 1h/0min). Patrón de dinámica metabólica: acumulativo frente a aclaramiento. Seguimiento tras tratamiento en todos los pacientes y de forma dirigida, cuando éticamente es posible.


Cincuenta y tres focos prostáticos, en ninguna de las imágenes precoces actividad urinaria: Patrón acumulativo en 42, porcentaje de aumento: 0min/1h: +16,7% (χ20,94); 1/2h: +10,0% (χ20,83). Patrón aclaramiento en 11, porcentaje de reducción: 0min/1h: 21,4% (χ20,91); 1/2h: −7,7% (χ20,85), correspondiendo en 7 a estadificación y 4 a posradioterapia.

Todos los focos infradiafragmáticos (n: 24) mostraron dinámica acumulativa, porcentaje de aumento: +9,1% (χ20,97), todas ellas visibles en el primer estudio.

De los 12 focos supradiafragmáticos, 8 mostraron aclaramiento, porcentaje de reducción: −13,0% (χ2 0,95). Los otros 4 dinámica acumulativa, porcentaje de aumento: +13,0% (χ2 0,96), siendo valorados invasivamente.

Todos los focos óseos (n: 18) mostraron dinámica acumulativa, porcentaje de aumento: +17,1% (χ20,95), todas ellas visibles en el estudio 1h.


En la valoración prostática la mejor técnica doble fase es 0min/1h. En la diferenciación de adenopatías supradiafragmáticas es aconsejable la técnica de doble fase: 1/2h. Para la infiltración infradiafragmática y ósea, ante hallazgos dudosos, las imágenes 2h aumentan la confianza diagnóstica.

Palabras clave:
PET/TC con 18F-Colina
Cáncer de próstata
Protocolos de adquisición


These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más